Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.
Geoffrey Liu, MSc, MD
Advertisement
Geoffrey Liu, MSc, MD, is a senior scientist at Princess Margaret Cancer Centre and a professor in the Epidemiology Division at Dalla Lana School of Public Health of the University of Toronto in Canada.
Articles by Geoffrey Liu, MSc, MD
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5